Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL943969 | 0.74 | KDM4E (0.44) | CNR2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1114285 | 0.68 | CYP2D6 (0.44) | CYP2D6CYP1A2LMNAALDH1A1MEN1 | |
| SCHEMBL6603272 | 0.68 | CYP2D6 (0.44) | CYP2D6CYP1A2LMNAALDH1A1MEN1 | |
| Tert-Butylamine SCHEMBL2724638 | 0.68 | ALDH1A1 (0.52) | CYP2D6CYP1A2LMNAALDH1A1MEN1 | |
| SCHEMBL550359 | 0.67 | CYP2D6 (0.47) | CYP2D6CYP1A2LMNAALDH1A1MEN1 | |
| SCHEMBL4429977 | 0.66 | ALDH1A1 (0.44) | CYP2D6CYP1A2LMNAALDH1A1MEN1 | |
| SCHEMBL5422817 | 0.66 | GAA (0.52) | CYP2D6CYP1A2LMNAALDH1A1CYP2C9 | |
| SCHEMBL10749800 | 0.66 | GAA (0.52) | CYP2D6CYP1A2LMNAALDH1A1CYP2C9 | |
| SCHEMBL11721219 | 0.65 | ALDH1A1 (0.43) | CYP2D6CYP1A2LMNAALDH1A1MEN1 | |
| Propyne SCHEMBL28767946 | 0.65 | ALDH1A1 (0.52) | CYP2D6CYP1A2LMNAALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3026046-A1 | THIAZOLES AS CANNABINOID RECEPTOR LIGANDS | AbbVie Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2376462-B1 | THIAZOLES AS CANNABINOID RECEPTOR LIGANDS | ABBVIE INC (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8895592-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2376462-A1 | Thiazoles as cannabinoid receptor ligands | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20100216760-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2010071783-A1 | THIAZOLES AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216760-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | CYP2D6 1464/4885CYP1A2 1015/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.